Tharimmune Reports Preclinical Data for Dual-Target Biologics

MT Newswires Live
04-07

Tharimmune (THAR) reported Monday preclinical data from its expanded pipeline featuring dual-target biologics HS1940 and HS3215, which it says was "positive."

HS1940 is designed to bind to both programmed death-1, or PD-1, and vascular endothelial growth factor, or VEGF, potentially improving treatment outcomes for various cancers. HS3215 targets human epidermal growth factor receptors 2 and 3, or HER2 and HER3, key proteins involved in cancer growth. HS1940 and HS3215 were developed using Tharimmune's antibody engineering platform, EpiClick Technology, the company said.

The company also said it aims to further improve the binding characteristics of HS1940 and present more data at future conferences, with plans to begin investigational new drug, or IND-enabling studies in 2025. Tharimmune also said it is conducting preclinical studies on HS3215 and plans to advance it into clinical trials after IND-enabling studies.

Shares of Tharimmune were down nearly 7% in recent trading.

Price: 1.10, Change: -0.08, Percent Change: -6.86

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10